LOGIN
COA: Use of rhPDGF in a collagen matrix effective for foot and ankle fusion
July 2013
COA: Use of rhPDGF in a collagen matrix effective for foot and ankle fusion
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Outcomes of Hindfoot and Ankle Fusions Treated with Augment Injectable Bone Graft: Results of a Prospective Randomized Controlled Trial
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
217 patients undergoing hindfoot and ankle reconstruction were randomized to receive either the Augment Injectable Bone Graft, containing platelet-derived growth factor (rhPDGF-BB in a tricalcium phosphate (B-TCP)/collagen matrix, or an autogenous bone graft to compare bone fusion and clinical success rates. Patients were to be assessed over a 1 year period; preliminary results indicated that fusi...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.